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Abstract
Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid
acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational
landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new
therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as
effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found
miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR-
654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of
ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant
direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to
ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of
miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach
for ovarian cancer.
Introduction
Ovarian cancer (OC) is the most lethal gynecological
malignancy [1] and includes different subtypes, being high-
grade serous carcinoma (HGSC) the most common and
aggressive subtype [2]. Despite the efforts devoted to
improve early diagnosis [3, 4], the disease still remains
largely incurable, in part due to the presence of ascites in
advanced stages [5]. Over the past 50 years, the first-line
chemotherapy for OC, composed mainly of platinum and
taxane derivatives [6], has neither varied nor resulted into a
significant improved overall survival [6]. Recently, targeted
therapies against PI3K, MEK, EGFR and key regulators of
the cell cycle, among others [7] are on the horizon of new
treatments for OC. Still under the regimen of recurrent OC,
some improvements have been achieved with the intro-
duction in the therapeutic pipeline of anti-angiogenic agents
[7], and PARP inhibitors for BRCA mutation carriers [8]
and patients with a “BRCAness” phenotype [9]. However,
and due to the heterogeneity of the disease, a deeper
molecular understanding of the tumor biology is needed to
generate novel and efficient therapies.
Recent evidence suggests that modulation of microRNA
(miRNA) levels, a type of small (∼18–22 nt) non-coding
RNAs, can be a novel therapeutic approach for cancer and
other diseases [10] thanks to the ability of a particular
miRNA to target multiple genes that might be altered in
specific disease conditions. A considerable number of pre-
clinical studies involving miRNA therapeutics have been
conducted over the last years [11]. Several miRNA have
been shown to be downregulated in ovarian tumors, asso-
ciated to shorter or poorer overall survival and related to
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better response to chemotherapy [12–16]. However, only
few of them have moved into clinical trials [10], such as the
first phase I study in humans that has been completed in
2017 using miR-34a for the treatment of advanced solid
tumors [17].
The heterogeneity of miRNA-detecting platforms and
patient cohorts hamper the interpretation of the results
across studies and the implementation of miRNAs as ther-
apeutic tools in OC [12]. Here, we provide an extensive
study of miRNA expression in more than 200 tissue sam-
ples, and the use of clinically representative models that
better recapitulate the human disease. We have found that
the restoration of miR-654 expression levels significantly
inhibited cell proliferation and induced apoptosis in vitro,
in vivo and in ex vivo patient derived-ascitic cell models.
Further investigation into its mechanism of action showed
that miR-654 altered the expression of CDCP1 and
PLAGL2, thereby impacting on the oncogenic function of
MYC, AKT and Wnt pathway, opening novel possibilities
for the treatment of OC.
Results
MmiR-654 is downregulated in ovarian tumors
In an attempt to identify new targets for OC therapy, we
analyzed miRNA expression levels in advanced-stage OC
patients, under the arguably hypothesis that deregulated
miRNA in shorter living patients could potentially be
involved in the disease progression and serve as novel
therapeutic targets. Patients were classified into two groups
(n= 107) according to an overall survival of less than 3 or
more than 8 years (short- and long-term survival; SSV and
LSV, respectively; Supplementary Table 1a). We initially
used a cohort of 27 OC FFPE primary tumors (Supple-
mentary Fig. 1a) and profiled miRNA levels. Thirty-two
miRNA were found differentially expressed between both
groups (Fig. 1a, Supplementary Data S1). Unsupervised
hierarchical clustering analysis showed that the majority of
patients clustered according to their survival group (Fig. 1a).
Next, we used an independent multicenter cohort of 80
FFPE samples (Supplementary Fig. 1a) to validate the
identified miRNA (Fig. 1a, Supplementary Data S1), and
found 4 miRNA, namely miR-654, miR-554, miR-409-3p
and miR-127-3p that displayed higher levels in tumors from
SSV compared to LSV patients with p-value < 0.05 and fold
change > 1.5 (Supplementary Fig. 1b, c).
We then modulated the expression of the 4-validated
miRNA in multiple OC cell lines and found that miR-654
overexpression decreased cell proliferation in all lines tested
(Fig. 1b), while its inhibition increased proliferation in 3 of
the 4 OC cell lines (Supplementary Fig. 1d). Despite this
was in apparent contradiction with the observation that
miR-654 levels were higher in SSV patients, the con-
sequences of its modulation in vitro suggests that miR-654
presumably acts as a tumor suppressor in OC. Supporting
this hypothesis we found lower levels of miR-654 in tumors
compared to benign ovarian tissues (Fig. 1c) (n= 84,
Supplementary Table 1b), which were further decreased in
the HGSC histology, the most aggressive type of OC (Fig.
1d). A small cohort from the initial screening, with extended
clinical follow up, revealed that the difference between SSV
vs. LSV samples, albeit significant in agreement to our
initial observation, was within the lower expression range
that tumoral samples display for miR-654 compared to
benign samples (Fig. 1c). Kaplan-Meier survival curves
from HGSC tumors (Supplementary Fig. 1c) reflected that
high miR-654 expression related to poorer survival (Sup-
plementary Fig. 1e), suggesting a prognostic role for miR-
654 levels within tumors. In addition, no differences were
found when tumors where grouped as early- or advanced-
stage OC (Supplementary Fig. 1f), or between paired tumor
and metastases samples from HGSC patients (Supplemen-
tary Fig. 1g) (Supplementary Table 1c), supporting the
hypothesis that the reduction on miR-654 levels may be
more related to the initiation of the disease, and points
towards a tumor suppressor role for miR-654.
MiR-654 promoter region is hypermethylated in OC
cell lines and tissues
MiR-654 is located in Chromosome 14, within the q32.31
chromosomal region, a region frequently altered in cancer
[18–20], including OC [13]. Here, we found hyper-
methylation in the CpG islands of 79 and 89% of tumors
and cell lines evaluated, respectively, with a β-value ≥ 0.5
(Fig. 1e). Accordingly, the levels of miR-654 sig-
nificantly raised upon DNA methyltransferase inhibition
in OAW28 cells and the same tendency was observed for
A2780 cells (Fig. 1f) (two of the cell lines that expressed
low miR-654 levels, Supplementary Fig. 1h; and high
levels of hypermethylation). This was accompanied by
increased expression of MEG3, GBGT1 and MAGE-A3
positive control genes [21–23] (Supplementary Fig. 1i).
Together, this suggests that hypermethylation could be
responsible in part for the low miR-654 levels found in
OC, despite other mechanisms may be regulating miR-
654 expression in OC.
Overexpression of miR-654 reduces cell viability and
sensitizes cells to paclitaxel in vitro
The effects of miR-654 ectopic expression were analyzed
and a 50% reduction in cell proliferation was observed
in SKOV3 and A2780 cells in a miR-654 overexpression
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time-course (Fig. 2a, Supplementary Fig. 2a, b). Cell death
was analyzed in 4 OC cell lines finding the number of
apoptotic cells significantly increased upon miR-654
transfection compared to miR-Control-cells (Fig. 2b, c),
which was confirmed by the cleavage of Caspase-3 and its
substrate PARP-1 (Fig. 2d). We found that miR-654 did not
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induce cell death in the presence of the caspase-inhibitor Q/
VD/OPH, thereby indicating that miR-654-induced cell
death is caspase-dependent (Supplementary Fig. 2c). Fur-
thermore, cell cycle profile analysis showed a subG1 peak at
96 h post-miR-654 transfection (Supplementary Fig. 2d),
consistent with the increased cell death observed, and a
slight increase in the percentage of cells in G1 (Supple-
mentary Fig. 2e), suggesting that miR-654 overexpression
caused an initial cell cycle delay that may add to the
reduced proliferation observed. To test whether miR-654
sensitize cells to paclitaxel, SKOV3 and A2780 cells were
treated with paclitaxel at different doses and transfected
with miR-654, showing a synergistic effect in reducing cell
viability (Fig. 2e, Supplementary Fig. 2f, g), and suggesting
that the combination of miR-654 and paclitaxel may be a
suitable therapy for OC.
MiR-654 expression reduces the viability of OC
patient-derived ascitic cells
Tumor ascites, which survive in anchorage-independent
conditions growing as spheroids and drive OC progression
at later stages [24], are a major source of disease recur-
rence. Patient-derived ascitic cells were grown ex vivo to
evaluate the potential therapeutic role of miR-654 in
advanced disease stages, finding that miR-654 over-
expression significantly reduced the number, size and via-
bility of spheroids (Fig. 2f–h), and increased spheroid
caspase-dependent apoptosis (Fig. 2i). Altogether, this
mirrored the previous results observed in OC cell lines and
empowered in addition patient-derived ascites as ex vivo
models to evaluate novel therapies for advanced-stage OC
patients.
MmiR-654 overexpression impairs tumor growth
in vivo
To recapitulate in vivo the results obtained in vitro, 2 × 106
miR-Control and miR-654 transfected SKOV3 cells were
injected in the flank of nude mice (n= 12/group) and
monitored as shown in Fig. 3a. MiRr-654 overexpression
was confirmed before cell implantation, at 5 days post-
injection and at the end of the experiment (Fig. 3b–d). Eight
days post-injection, all miR-Control mice developed tumors
whereas only 40% of miR-654 mice did so (Fig. 3e). Sig-
nificant differences in tumor volume were visible at 11 days
post-injection and maintained through the experiment (Fig.
3f). Mice were sacrificed at day 25 and tumors were
weighted and imaged, finding smaller tumors in the miR-
654 group (Fig. 3g, h). Importantly, miR-654 levels inver-
sely correlated with tumor volume (r=−0.95, Fig. 3i) and
weight (r=−0.8619, Supplementary Fig. 3a) and both
positively correlated between each other, confirming the
accuracy of the measures (Supplementary Fig. 3b).
Moreover, reduced cellularity, larger areas of collagen
deposition and decreased percentage of Ki67 positive cells
were visible in mice sacrificed at day 5 post-injection (Fig.
3j, k) and remained until the end of the experiment (Sup-
plementary Fig. 3c); phenotype commonly observed after
chemotherapy, where the extracellular matrix fuels the
empty spaces left by death cells [25]. Of note, some tumors
from the miR-Control group invaded the dermis, while none
of the miR-654 mice group did so (Supplementary Fig. 3d).
Altogether, miR-654 reduced tumor growth in vivo, indu-
cing regressive changes at initial steps after the engraftment
determining the tumor fate.
MiR-654 targets multiple genes involved in
apoptosis, cell proliferation and survival pathways
To understand the molecular mechanisms regulated by miR-
654, we followed the workflow shown in Fig. 4a. First, a
whole transcriptome 3′UTR search for miR-654 binding
sites was conducted using the in silico platform miR-
Walk2.0 [26] that revealed a list of 2302 putative target
genes. Of those, 46 were predicted by at least 5 different
algorithms (Supplementary Table 1l) and 14 were finally
selected according to previously described functions related
to the observed miR-654 phenotypes. Upon miR-654
overexpression 5 of those 14 candidates suffered a reduc-
tion in the mRNA levels in SKOV3 and A2780 cells with
more than 50% reduction in at least one of them (Fig. 4b,
red asterisks) (Supplementary Fig. 4a). At protein level,
HAX1, RAB1B and PLAGL2 appeared decreased in both
cell lines at different time points post-transfection, while
CDCP1 and PBX3 protein levels did so only in SKOV3
Fig. 1 Decreased miR-654 expression and hypermethylation of its
locus are found in OC. a Unsupervised hierarchical clustering of the
32 differentially expressed miRNA (FDR < 0.05) found in the dis-
covery phase (n= 25, as two patients were outliers; see also Supple-
mentary Methods), in SSV compared to LSV patients. b Evaluation of
the proliferation effect in miRNA mimic-transfected indicated OC
cells 96 h post-transfection. Graph represents the mean ± SEM of three
independent experiments (n= 6/condition). c Relative miR-654
expression levels in benign lesions (n= 29) compared to ovarian
tumors (n= 55); and in a cohort of LSV vs. SSV tumors (n= 8)
randomly selected fro (a). d Relative miR-654 expression levels in
ovarian tumors according to their histology. e Methylation analysis of
the 13 CpG sites of the miR-654 locus in OC cell lines (top) and
tumors (bottom). f MiR-654 levels upon treatment with 1 μM of 5-
AZA-2’-deoxycytidine at the indicated times. Graph represents the
mean ± SEM of 2 independent experiments. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001. p values were calculated using
unpaired student’s t-test for (b) and (f), and non-parametric Mann-
Whitney tests for (c) and (d). See Supplementary Methods for statistics
of (A)
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cells (Fig. 4c), possibly due to different protein stability
between both cell lines. Furthermore, luciferase-reporter
assays upon miR-654 overexpression showed a significant
reduction in luciferase activity for all 3′UTR engineered
regions and this was significantly rescued when seed
sequences in the 3′UTR regions of all targets were mutated
(Fig. 4d, Supplementary Table 1k), indicating a direct
modulation of these genes by miR-654.
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CDCP1 and PLAGL2 knockdown phenocopies miR-
654 overexpression in vitro
To gain insights into the molecular mechanisms driven by
miR-654 through its targets, HAX1, RAB1B, PBX3,
CDCP1 or PLAGL2 were silenced in SKOV3 cells (Sup-
plementary Fig. 4b). CDCP1 and PLAGL2 silencing best
recapitulated the effects of miR-654 overexpression, redu-
cing proliferation (Fig. 4e) and increasing the percentage of
apoptotic cells comparably to miR-654 overexpression (Fig.
4f, g). In addition, overexpression of miR-654 in the ex vivo
patient-derived ascitic cell models resulted in diminished
protein levels of CDCP1, PLAGL2 and RAB1B (Fig. 4h),
thereby suggesting that these 3 genes could be mediators of
the miR-654 effects in this context. Interestingly, we found
higher CDCP1 and PLAGL2 levels in HGSC OC samples
compared to benign lesions (Fig. 4i), while RAB1B levels
were similar between groups (Supplementary Fig. 4c). We
found that CDCP1 or PLAGL2 and miR-654 levels inver-
sely correlated (although did not reach statistically sig-
nificance for PLAGL2 and miR-654) (Supplementary Fig.
4d). This suggests that CDCP1 correlates better with miR-
654 levels and the clinical parameters, indicating a close
relation of miR-654/CDCP1 with OC progression. Instead,
the lack of significant correlation between PLAGL2 and
miR-654 in individual patients might indicate a more
complex regulation of this target. Together, these results
support the clinical relevance of targeting CDCP1 and
PLAGL2 by miR-654 in OC.
MiR-654-CDCP1/PLAGL2 converge on the MYC, AKT
and Wnt gene sets
For the abovementioned reasons, we focused on under-
standing CDCP1 and PLAGL2 signaling networks regu-
lated by miR-654 hereafter. To this end, a whole
transcriptome analysis was performed after silencing
CDCP1 or PLAGL2 in SKOV3 cells (Fig. 5a). Principal
component analysis (PCA) segregated siControl vs.
siCDCP1 or siPLAGL2 samples indicating a consistent
transcriptional impact after both gene depletions (Fig. 5b),
and a high number of differential expressed genes (Fig. 5c,
FDR < 0.25 and fold change > ± 1.5). Interestingly, 70 and
60 genes were commonly down and upregulated, respec-
tively, by CDCP1 and PLAGL2 silencing (Fig. 5d),
denoting that part of the transcriptional changes partially
overlapped between both genes. Functional annotation
using DAVID bioinformatic tools showed that CDCP1 and
PLAGL2 depletions significantly impacted on genes asso-
ciated to canonical KEGG pathways in cancer (Fig. 5e, >10
genes and p < 0.05), and to GO terms related to cell pro-
liferation and apoptotic processes, among others (Supple-
mentary Fig. 5a). Furthermore, gene set enrichment analysis
(GSEA) was performed using major gene set collections,
resulting in a vast number of significantly enriched gene
sets for both gene conditions (Supplementary Fig. 5b).
Then, gene sets related to apoptosis, HIF-1, focal adhesion,
Wnt, MYC, actin cytoskeleton, MAPK, AKT, FoxO, Pro-
teoglycan in cancer, and angiogenesis were used for a
second GSEA, according to the most represented functions
found in the DAVID analyses and the first GSEA. Notice-
ably, several enriched gene sets related to MYC, AKT and
Wnt pathway were commonly altered by CDCP1 and
PLAGL2 knockdown, among others (Fig. 5f–h, Supple-
mentary Fig. 5c, and Supplementary Methods). MYC levels
appeared downregulated by both CDCP1 and PLAGL2
depletions (Fig. 5h, top left), as well as several regulators of
the Wnt pathway such SMURF2 and DKK1 (Fig. 5h, top
right). Additionally, several cyclin-dependent kinases
(CDKs) such as CDK2 and CDK4 diminished upon
PLAGL2 depletion (Fig. 5h, bottom right), as well as the
levels of AKT2 and retinoblastoma (RB) (Fig. 5h, bottom
right), thus suggesting that reduction of the expression of
these genes might contribute to the effects of miR-654
overexpression on cell survival. In agreement with the
hypothesis that part of the miR-654 phenotypic effects
occur through the reduction of CDCP1 and PLAGL2 levels
Fig. 2 MiR-654 expression reduces viability of OC cells and spheroids
from patient-derived ascites, induces apoptosis and cooperates with
paclitaxel to impair OC growth. a Time course proliferation assay in
SKOV3 and A2780 cells after miR-654 or miR-Control transfection at
24, 48, 72, and 96 h (n= 5/condition). b Representative images of the
Hoechst nuclear staining upon overexpression of miR-654 or miR-
Control. Bar, 50 μm. c Quantification of B was performed based on all
cells from 4 representative images (n= 3/condition). d Western blot of
PARP-1 and Caspase-3 in SKOV3 and A2780 cells at 96 h post-
transfection with miR-654 or miR-Control. e Combination index (CI)
of miR-654 (constant, 25 nM) and paclitaxel at a 1/2×, 1× and 2× of
the IC50 was calculated, by the Chou–Talalay method. DMSO and
miR-Control were used as controls (n= 6/condition). Plotted data are
CI values at the corresponding % of fraction affected, when treated
with different doses of paclitaxel for each cell line (IC50= 25.2 and
8.84 nM for SKOV3 and A2780, respectively). * means comparison of
each condition vs miR-Control/DMSO; # Combo condition vs miR-
654/DMSO, +Combo condition vs the miR-Control/Paclitaxel. f The
number of spheres was scored after 96 h post-transfection with miR-
Control and miR-654 in 4 OC patient-derived ascitic cells grown under
anchorage independent conditions and classified as being between
50–100 μm, ≥100 μm, and ≥200 μm in diameter. g Representative
images of the indicated ascitic primary cells used for the sphere
forming capacity assay. The miRNA-transfection control labeled with
Dy547 was used to monitor transfection. Bar, 100 μm. h Viability
assay (MTS) was performed at 96 h post-transfection with miR-
Control or miR-654 in the indicated OC patient-derived ascitic cells
cultured under anchorage independent conditions. i Spheres were used
for protein extraction and Western blot analysis with the indicated
antibodies 96 h post-transfection with miR-Control and miR-654.
Graph represents mean ± SEM of three independent experiments in
plots (a), (c), and (e). *, #, +p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001; ns not significant. p values were calculated using unpaired
student’s t-test
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in OC, we found diminished protein levels of MYC, p-
AKT, CDK2/4, RB, p-RB and β-catenin (β-cat, gene sym-
bol CTNNB1), and increased levels of p27 (also CDKN1B)
upon overexpression of miR-654 in SKOV3 cells (Fig. 5i),
confirming the expected molecular events that accompany a
slower cell cycle progression and a decreased cell survival.
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We also sought to explore whether these pathways were
modulated by miR-654 in the patient-derived ascitic cell
models and, concurring with our previous results, the pro-
tein levels of MYC, p-AKT, CDK2/4 and β-cat were
diminished upon miR-654 overexpression in patient-derived
ascites (Fig. 5j). Altogether, these results suggested that the
tumor suppressor functions of miR-654 are mediated, in
part, by the modulation of its direct targets, CDCP1 and
PLAGL2, which in turn modulate key pathways in OC,
such as MYC, AKT and Wnt pathways (Fig. 6).
Discussion
The clinical management of OC remains a challenge due to
the fact that high-grade histologies generally become
resistant to standard therapies [3]. Moreover, the ability to
translate the increasing knowledge on the genetic alterations
into more effective treatments for OC had, so far, limited
clinical impact in part due to the heterogeneity of the dis-
ease. In the present study, we found 4 miRNA whose levels
were higher in tumors from SSV OC patients, suggesting at
first glance an oncogenic role for them. However, the
restoration of miR-127-3p and miR-654 reduced cell pro-
liferation, evoking tumor suppressive rather than oncogenic
properties. A plausible explanation is that SSV tumors
could be more infiltrated with certain cell types from the
immune system that have been associated to poorer prog-
nosis in OC [27], which may contribute to the increased
levels of miR-654 found in SSV compared to LSV tumors
(our preliminary results). In agreement with the previous
phenotype, we found higher miR-654 levels in normal
samples than in OC tumors, which was also seen for miR-
127-3p [28], suggesting that their loss may contribute to the
initiation of OC.
In accordance with the in vitro results, we proved for the
first time that the ectopic expression of miR-654 reduced
tumor growth in vivo and reduced viability of patient-
derived ascites grown ex vivo. Importantly, this is the first
report that tested the effect of modulating a tumor sup-
pressor miRNA on the sphere forming capacity and viabi-
lity of OC patient-derived ascites. This model is not without
limitations, as their use is limited to 4–6 passages [29], but
our results clearly suggest that the tumor-suppressive effects
of miR-654 could be of clinical relevance. Nonetheless,
other hits presumably accompany miR-654 loss in OC cell
transformation, as inhibition of miR-654 in non-tumoral
immortalized ovarian surface epithelial (IOSE) cells per se,
does not impair the cell death by contact inhibition typically
observed in these cells (not shown).
MiR-654 was firstly identified and annotated by Cum-
mins JM et al. [30] in 2006, it is located in the 14q32
chromosomal region, and recently found downregulated in
classic Hodgkin lymphoma [31] and breast cancer [32].
Here, we found that the 14q32 region is hypermethylated in
human OC tissues and cell lines, and an increased expres-
sion of miR-654 was obtained upon DNA methyltransferase
inhibition in vitro, suggesting that epigenetic silencing
could be one of the possible mechanisms of miR-654 reg-
ulation. Concurring with this observation, the DLK1-MEG3
(Dlk1-Gtl2) cluster, which contains miR-654 in humans
[33], has been found epigenetically downregulated in OC
through hypermethylation [13].
To date, little is known about the downstream miR-654-
dependent signaling, and EPSTI1 for breast [32] and AR for
prostate [34] cancer were the only 2 direct targets identified
thus far. In this study, we found HAX1, RAB1B, PBX3,
CDCP1 and PLAGL2 to be direct miR-654 targets, and their
silencing revealed that the miR-654-related phenotype in OC
is primarily caused by direct targeting of CDCP1 and
PLAGL2 oncogenes. Furthermore, CDCP1 and PLAGL2
levels were found to be increased in ovarian tumors com-
pared to normal samples, which has also been seen in leu-
kemia [35] for PLAGL2, and in other malignancies including
OC [36, 37] for CDCP1, supporting their role in OC pro-
gression and turning them into attractive therapeutic targets.
Our transcriptomic analysis after CDCP1 and PLAGL2
depletion defined both genes as master regulators of MYC,
AKT and Wnt pathway in OC cells, and several of the
canonical genes altered at the transcriptome level were
confirmed at protein level in OC cell and primary patient-
derived ascites. CDCP1 (CUB domain-containing protein 1)
is a type I transmembrane glycoprotein, that activates cell
survival pathways in OC to mediate spheroid formation and
chemoresistance through the activation of p the AKT
pathway [36, 37]. PLAGL2 belongs to the PLAG family of
zing finger proteins [38] and acts as an oncogene by
enhancing anchorage independent growth and inducing
Fig. 3 Overexpression of miR-654 impairs tumor growth in vivo. a
Schematic representation of the in vivo model timeline. b-d Relative
expression of miR-654 levels analyzed by RTqPCR in SKOV3 cells
before mice injection (b), in two mice per group at day 5 post-injection
(c), and in the 20 mice xenografts at the end-point of the experiment
(d). e Tumor-free survival curve of mice bearing OC xenografts
transfected with miR-Control (continuous line) or miR-654 (dotted
line). f Tumor volume of mice injected with either miR-Control or
miR-654 transfected SKOV3 cells (n= 10/group), measured for
25 days. g Weight of resected tumors. h Macroscopic images of
resected tumors at the consecution of the experiment. Bar: 1 cm. i
Spearman correlation between miR-654 levels and tumor volume of
miR-654 mice group. j Representative images of H&E staining of the
OC xenografts after 5 days post-injection. Black arrows are showing
areas of collagen deposition by the reduced tumor cellularity in miR-
654 tumors. k Representative microscopic images of Ki67 staining of
the OC xenografts after 5 days post-injection. White arrows are
showing remaining areas of non-proliferating tumor cells (without
Ki67 staining). **p < 0.01; ***p < 0.001; ****p < 0.0001. p values
were calculated using unpaired student’s t-test for (d), (e), (f), (g)
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tumors in mice [38], in part through its downstream effector
p-AKT [39]. Here, we found reduced AKT2 mRNA levels
by PLAGL2 inhibition, which together with the reduced
p-AKT levels observed upon miR-654 overexpression,
suggest a possible contribution of CDCP1 and PLAGL2 to
the regulation of AKT pathway through miR-654 signaling.
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A striking decrease in p-RB was also observed upon
miR-654 expression, possibly caused by the reduced p-
AKT and CDK2/4 levels observed. In addition, 2 CDK
regulatory proteins, CKS1B and p27, were found under and
overexpressed, respectively, upon both CDCP1 and
PLAGL2 inhibition, suggesting that cell cycle progression
and survival was diminished in OC cells in part through
defective CDKs function.
Importantly, this is the first report that relates CDCP1 and
PLAGL2 with MYC, a master regulator of cancer cells [40].
MYC has been found to be mutated and amplified in HGSC
[3, 16] and a good candidate for targeting platinum-resistant
OC [41], thereby suggesting that these patients would likely
benefit of a miR-654-based therapy. Furthermore, several
genes related to the Wnt pathway were found to be altered
after CDCP1 and PLAGL2 depletion in OC cells, and
reduced total β-cat protein levels were observed upon miR-
654 overexpression in OC cells and primary ascites con-
firming the modulation of the Wnt pathway by miR-654.
Whereas PLAGL2 has been shown to activate Wnt signaling
in glioblastoma and colon cancer [42, 43] thereby resulting in
an accumulation of total β-cat levels, CDCP1 had never been
previously related to the Wnt pathway, which further sup-
ports the use of miR-654 as a potent Wnt-like inhibitor,
through targeting CDCP1/PLAGL2.
In summary, miRNA-654 acts transversally against
multiple pathways, including MYC, AKT and Wnt
signaling in OC, reducing cell proliferation and promoting
cell death (Fig. 6). We found it downregulated in ovarian
tumors, together with elevated levels of its direct targets
CDCP1 and PLAGL2, which might contribute on boosting
OC cells tumorigenicity. In summary, these results pinpoint
that miR-654 restoration may be an effective strategy for the
treatment of OC in combination with the current therapies.
Materials and methods
Human samples
Formalin-fixed paraffin embedded (FFPE) primary tumors
from 107 advanced stage OC patients were obtained from
Vall Hebron University Hospital (VHUH) (Barcelona,
Spain) and 5 other national collaborative hospitals (Sup-
plementary Table 1a) used for miRNA array analyses. Fresh
tissues including benign lesions and ovarian tumors (Sup-
plementary Table 1b), and 21 patient-matched paired FFPE
tumors and metastases were obtained from VHUH (Sup-
plementary Table 1c). All patients gave their written
informed consent, and fresh tissues were collected con-
forming to the Institutional Review Board (IRB)
(PRAMI3082015).
Cell culture
Commercial cell lines, SKOV3, OAW42, 59M, OAW28,
OVCAR4, TOV112, OV90, A2780, A2780cis, BIN67,
IGROV1, IOSE-503, IOSE-385 and HEK293T were cultured
with indicated culture media (Supplementary Table 1d). Cells
were regularly tested for mycoplasma contamination and
authenticated by short tandem repeat profiling.
For patient-derived ascites primary cultures, cells were
obtained from malignant ascitic fluid collected at the time of
the surgery under the IRB approval, (Supplementary Table
1e). Ascitic primary cultures were established following pro-
cedures previously described [29]. Immediately after surgery,
the ascitic fluid was mixed (1:1) with Mix medium (Supple-
mentary Table 1e). After 1 week, medium was replaced to
remove any remaining blood cells and adherent cells were
grown until 4–6 passages. All cells were maintained at 37 °C
in a saturated atmosphere of 95% air and 5% CO2.
Human miRNA microarray
For miRNA expression profiling, TaqMan® Array Human
MicroRNA A+B Cards Set v3.0 (Applied Biosystems,
CA, USA) were used to analyze a total of 768 miRNA
sequences by 2−ΔΔCt method [44]. Samples from 27 FFPE
tumors (Supplementary Table 1a) were used for the dis-
covery phase. Total RNA was used for the reverse
Fig. 4 MiR-654 targets multiple cancer-related genes involved in
apoptosis, cell proliferation and survival pathways, unveiling CDCP1
and PLAGL2 as relevant direct targets in OC. a Schematic repre-
sentation of the workflow followed to find miR-654 target genes. b
Relative mRNA expression levels of the indicated putative miR-654
target genes at 48 h post-transfection with miR-654, miR-Control or
MOCK-non-transfected SKOV3 (top panel) and A2780 (bottom
panel) cells. Red asterisks point to the putative miR-654 targets
selected for protein level determination. c Representative Western blot
for the indicated proteins at 48, 72 and 96 h post-transfection in
SKOV3 (left panel) and A2780 (right panel) cells. Asterisk points at
the specific band. d Luciferase assay performed in HEK-293T cells co-
transfected with the indicated luciferase-reporter vector (corresponding
WT and MUT 3’UTR regions for each target, respectively) and miR-
654 or miR-Control mimics. e Proliferation assay after individual
silencing of the miR-654 targets genes (n= 6/condition). f Repre-
sentative images of the Hoechst nuclear staining upon transfection
with miR-654 or miR-Control mimics, siR-Control or the corre-
sponding siRNA for each of the target genes at 96 h post-transfection
of SKOV3 cell line. Bar, 50 μm. g Quantification of F from four
representative images (n= 3/condition). h Western blot of the indi-
cated miR-654 targets in three patient-derived ascitic cells from OC
patients transfected with miR-Control or miR-654 for 96 h. i Relative
mRNA expression of CDCP1 and PLAGL2 analyzed in human
ovarian tissues (n= 65 and n= 68, respectively, according to the
outlier samples detected for each gene and including only HGSC
tumors). b benign lesions, T tumors. Graphs represent the mean ± SEM
of four independent experiments for (d), (e), and (g). *p < 0.05; **p <
0.01; ***p < 0.001; ****p < 0.0001. P values were calculated using
unpaired student’s t-test for (d), (e) and (g), and non-parametric Mann-
Whitney test for (i)
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transcription (RT) of 300 ng by using TaqMan MicroRNA
RT Kit and the pool Set v3.0 of MegaplexTM RT Primers A
+ B (Applied Biosystems, CA, USA). Targeted
preamplified cDNA was obtained by using MegaplexTM
PreAmp Primers, Human Pool Set v3.0 A+ B and Taq-
Man® PreAmp Master Mix 2 × (Applied Biosystems, CA,
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USA). Two miRNA array cards were performed per patient
in a 7900 ABIPrism System (27 cards A, 27 cards B).
Custom RT and Preamp primer pools were used to validate
the 32 differentially expressed miRNAs in 80 FFPE tumors
(Supplementary Table 1a), by using Custom TaqMan® Array
MicroRNA Cards following the manufacture instructions.
RTqPCR
For miRNA analyses, 25 ng of total RNA was used for RT
of each individual miRNA, by using specific TaqMan
probes (Supplementary Table 1f). Hsa-miR-572 was used as
endogenous control. For mRNA analyses, 1 μg of total RNA
was used for RT using SuperScript III enzyme (Invitrogen).
Power SybrGreen Master MIX (Cat# 4367659) was used to
analyze mRNA levels by the corresponding designed pri-
mers (Supplementary Table 1g). GAPDH was used as
endogenous control. Human samples were randomized for
RNA extractions, RT reactions and RTqPCR analyses in all
cases. Relative quantification of gene expression was per-
formed with the 2−ΔΔCt method [44].
DNA methylation microarray
DNA methylation data was obtained from Illumina Infinium
Human Methylation450 BeadChip arrays, and was down-
loaded from the TCGA portal [16], GSE81224 dataset [45],
and the Cancer Epigenetics and Biology Program (PEBC)
dataset (unpublished) for OC primary tumors (n= 35); and
from the GSE68379 dataset [46] for OC cell lines (n= 43).
Briefly, the GenomeStudio 2010.3, Methylation Module
1.8.5 was used as previously described [47] to calculate the
methylation β-values of the 13 CpG sites of the miR-654
chromosomal region 14q32.1. The percentage of samples
being hypermethylated was obtained by the average β-value
of the 13 CpG sites.
DNA demethylating assay
OAW28 and A2780 cells were treated with DMSO or the
DNA methyltransferase inhibitor 5’AZA-2’desoxycytidine
(Sigma). At the indicated time points, cells were used for
miR-654 evaluation. MEG3 (Chr.14), GBGT1 (Chr.9) and
MAGE-A3 (Chr.X) genes were used as positive control.
Cell proliferation assay
Cells were reversely transfected with 25 nM of miRIDIAN
miRNA mimic Negative Control, miRNA mimics or
antagomiRs (Supplementary Table 1h), or with 50 nM of
the indicated siRNAs (Supplementary Table 1i) using
Lipofectamine® 2000 and seeded at 3·103–10·103 in 96-well
plates (n= 6/condition). At the indicated time points, cells
were fixed with 4% formaldehyde, stained with 0.5%
crystal violet, dissolved with 15% acetic acid and measured
at 590 nm.
Protein extraction and western blot
Cells were harvested in RIPA buffer (Tris HCl 1.5 M pH=
8.8, NaCl 5M, Triton X-100, EDTA 500 mM) with pro-
tease and phosphatase cocktail inhibitors (1183170001,
P5726, P0044, Sigma). Lysis was done on ice for 1 h
with 30 sec vortex/15 min. Proteins (20–80 ug) were
resolved on 8–15% tris-glycine PAGE or pre-cast elec-
trophoresis gels (Thermo Fisher), and transferred onto
PVDF membranes, which were blocked for 1 h with 5%
non-fat milk (Panreac) or 5% BSA (Sigma) and probed
overnight at 4 °C with the indicated antibodies (Supple-
mentary Table 1j). After 1 h incubation with horseradish
peroxidase-conjugated secondary antibodies signal was
acquired with Immobilon Western (Millipore) or ECL
(GE Healthcare).
Cell death assay
Cells were reversely transfected with Negative Control or
miR-654 mimics (25 nM), or with the indicated siRNAs
(50 nM) and plated in 24-well plates (15 × 103 – 10 × 104
cells/well) and 96 h post-transfection cell death was
Fig. 5 miR-654 impacts on several oncogenic pathways through
PLAGL2 and CDCP1 in OC. a Levels of CDCP1 and PLAGL2
depletions analyzed at mRNA level before microarray analysis was
performed in SKOV3 cells (n= 3/condition). b PCA was performed
by Affimetrix Expression Console software to show segregation of
distinct expression profiles for siCDCP1 (left) and siPLAGL2 (right)
vs. siControl cells. c Summary of the deregulated genes upon CDCP1
and PLAGL2 silencing (FDR < 0.05 and fold change > ± 1.5). d Venn
diagram with downregulated (top) and upregulated (bottom) genes
upon CDCP1 and PLAGL2 silencing compared to siControl cells
(FDR < 0.25 and fold change > ± 1.5). e KEGG pathway analysis by
DAVID bioinformatic tool, using differentially expressed genes with
FDR < 0.05 from CDCP1 (left) and PLAGL2 (right) depletions com-
pared to siControl cells. f GSEA: gene sets collections related to the
indicated processes were downloaded from MSigDB.v6 and used for
the analyses. Total number of enriched gene sets with FDR< 0.25 or p <
0.05 were plotted regarding each collection and gene depletion. g
Representative GSEA curves for significant enriched gene sets related
to MYC, Wnt and AKT pathways upon CDCP1 and
PLAGL2 silencing compared to siControl cells. Corresponding nor-
malized enriched score (NES) and p-values < 0.05 for enriched gene
sets are included. h Heatmap depicting deregulated genes upon
CDCP1 and/or PLAGL2 depletion with FDR < 0.05 and fold change >
± 1.5, which are found in the collapsed gene lists of the enriched gene
sets for each pathway. i Western blots of the indicated proteins to
verify the alteration in MYC, AKT and Wnt signaling upon miR-654
overexpression in SKOV3 cells at 96 h post-transfection. Tubulin was
used as a loading control. j Western blot analyses in spheroids from
patient-derived ascitic cells collected after 96 h post-miRNA trans-
fection to verify the alteration in MYC, AKT and Wnt signaling in
human samples ex vivo
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evaluated as previously reported [48]. Briefly, cells were
stained with 0.05 mg/mL Hoechst 33258 and those with
uniformly stained chromatin or with fragmented and/or
condensed chromatin were scored as healthy or apoptotic,
respectively. Similarly, cell death was evaluated upon cas-
pase inhibition by using Q/VD/OPH at 10 μM in SKOV3
cells reversely transfected with Negative Control or miR-
654 mimics (25 nM) at 96 h post-transfection.
Combination index analysis
SKOV3 and A2780 cells transfected with Negative Control
or miR-654 mimics (25 nM) for 48 h were incubated with
paclitaxel for another 48 h at the indicated doses.
Combination index were determined by the Chou–Talalay
method using the Compusyn Software (ComboSyn Inc.,
Paramus, NJ, USA).
3D cultures from patient-derived ascitic cell
For sphere forming capacity, primary cultured ascitic cells
were reverse transfected with Lipofectamine 2000® and
Negative Control or miR-654 mimic (25 nM) and seeded at
15 × 103 in non-adherent 24-well plates (coated with 0.5%
agar in non-supplemented medium), in serum-free medium
(1:1-MCDB105:M199, Biological Industries) supplemented
with 1X B27 (Invitrogen), 2 mM L-glutamine, and 20 ng/
mL EGF and FGF (ProSpec-Tany Technogene Ltd). At
Fig. 6 Functions and model of the tumor suppressor role of miR-654
in OC. Proposed model of the tumor suppressor role of miR-654 in
OC. The high levels of hypermethylation could partly explain the low
miR-654 levels found in found in OC tumors and cells lines, which
accompanied by the enhanced CDCP1 and PLAGL2 levels might
contribute to boost the tumorigenicity of OC cells. Furthermore,
PLAGL2 and CDCP1 oncogenes appeared as relevant direct targets of
miR-654 in OC since they mediate at least part of the miR-654
function in the studied models. In addition, CDCP1 and PLAGL2
impact on key cell regulators (red or green for genes found over or
underexpressed upon CDPC1 and/or PLAG2 depletion and miR-654
overexpression), such as AKT, MYC and Wnt signaling pathways.
Therefore, we show that overexpression of miRNA-654 reduces cell
proliferation, induces apoptosis and sensitizes OC cells to paclitaxel
addition. Together, our results suggest that restoration of miRNA-654
levels and/or co-targeting of PLAGL2 and CDCP1 oncogenes may be
an efficient strategy for OC treatment in combination with the current
therapies
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96 h, spheres were collected for protein extraction, MTS
assay and for scoring. For MTS assays, tumor spheres were
washed with PBS 1 × , and disaggregated with 0.5 mL 1X
StemPro® Accutase® (ThermoFisher). PMS:MTS (1:20)
mixture was added 1:10 to each well containing 100 μL of
disaggregated cells, and measured at 2–5 h.
Luciferase reporter assays
DNA fragments containing the miR-654 binding sites for
each 3′UTR region (and their corresponding 3′UTR muta-
ted regions) of HAX1, CDCP1, PBX3, PLAGL2 and RAB1B
genes were synthesized (GeneArtTMStringTM, Thermo-
Fisher), amplified into the pCRTMII-Blunt-TOPO® vector
(Invitrogen), and cloned into the psiCHECKTM-2 vector by
using XhoI and NotI restriction sites (Supplementary Table
1k). 3’UTR luciferase reporter assays were performed as
previously described [49]. Briefly, HEK293T cells were
seeded at 2 × 104 cells/p96-well plates and co-transfected
with 50 ng of each psiCHECKTM-2–3′UTR vector and
25 nM of miR-654 mimic or Negative Control. Luciferase
assays were performed after 24 h using the Dual-Glo®
Luciferase Assay System (Promega) and renilla was nor-
malized to the firefly luciferase activity.
Mouse xenograft
All procedures were carried under the approval of the
Institutional Animal Care at VHIR (protocol number 85/
12). 2 × 106cells of SKOV3 explanted cells transfected with
Negative Control and miR-654 mimics (25 nM) were
injected in 8-week-old female NMRI-nude mice (Janvier,
n= 12/group) in 300 μL of PBS 1X and Matrigel (1:1).
Tumor volume was measured every 2–3 days using an
electronic caliper, and at day 25 mice were sacrificed and
tumors were removed and weighed. Each tumor was used
for H&E and Ki67 staining and for RNA extraction.
Human mRNA microarray analyses
SKOV3 cells transfected with siR-Control, siCDCP1 or
siPLAGL2 (n= 3) were used in the microarray analysis.
RNA concentration and quality were measured by Nanodrop
and RNA Nano Chip Bioanalyzer (Agilent Technologies),
and efficiency of CDCP1 and PLAGL2 depletion was mea-
sured by RTqPCR. Human ClariomTM S assay (Affymetrix)
was used to analyze whole-transcriptome expression profil-
ing, which detects more than 20,000 well-annotated genes.
The High Technology Unit (UAT) at VHIR performed all the
steps after RNA extraction, including the first and second
strand cDNA production, biotinylation, hybridization, label-
ing and scanning of the chips. Microarray raw data is publicly
available at the GEOarchive repository GSE113115.
Statistics
Sample size was chosen to ensure adequate statistical
power, according to the availability of the samples at the
VHUH and the prevalence of the disease. Unless otherwise
indicated, mean ± SEM values are the average of three
independent experiments. Statistical significance was
determined by unpaired Student’s t-test, assuming similar
variances (GraphPad Prism Software, La Jolla, CA, USA).
*p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001.
Identification of possible outliers was performed in all
human data (ROUT method), the normal distribution of the
data was verified (Shapiro-Wilk and Kolmogorov tests) and,
accordingly, non-parametric Mann-Whitney test was used
for comparisons between groups when analyzing human
ovarian tissues. Compute correlations between pairs of data
were performed by parametric Pearson and non-parametric
Spearman correlation analyses.
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